Literature DB >> 12667379

A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication.

Liya Zhou1, Joseph J Y Sung, Sanren Lin, Zhu Jin, Shigang Ding, Xuebiao Huang, Zhiwei Xia, Huilan Guo, Jianjun Liu, William Chao.   

Abstract

OBJECTIVES: To investigate the relationship between H. pylori infection, gastric cancer and other gastric diseases through the changes in gastric mucosa and the status of different gastric diseases within 5 years after H. pylori eradication in H. pylori-positive subjects in a high incidence region of gastric cancer.
METHODS: One thousand and six adults were selected from the general population in Yantai, Shandong province, a high incidence region for gastric cancer in China. Gastroscopy and Campylobacter-like organism (CLO) testing were performed on all subjects. Biopsy samples from the gastric antrum and body were obtained for histology and assessment of H. pylori infection. All H. pylori-positive subjects were then randomly divided into two groups: treatment group receiving Omeprazole Amoxicillin Clarythromycin (OAC) triple therapy and placebo as controls. These subjects were endoscopically followed up in the second and fifth year. We compared the endoscopic appearance and histology of the biopsy specimens from the same site obtained at the first and last visits.
RESULTS: All 552 H. pylori-positive subjects were randomly and evenly divided into treatment group or control group. During the five-year follow-up, the numbers of patients who continued to be negative or positive for H. pylori were 161 and 198, respectively. Statistical analysis revealed that: (1) At the initial visit, there were no significant differences in the severity and activity of inflammation, atrophy and intestinal metaplasia between the biopsy specimens from the antrum and body respectively in both groups. (2) The severity and activity of inflammation in both the antrum and body were markedly reduced after H. pylori eradication (P = 0.000). (3) Within five years after H. pylori eradication, intestinal metaplasia in the antrum either regressed or had no progression, while the proportion of intestinal metaplasia in the H. pylori-positive group increased significantly (P = 0.032). (4) After H. pylori eradication, the atrophy in both the antrum and body had no significant regression. The P value was 0.223 and 0.402, respectively.
CONCLUSIONS: H. pylori eradication results in remarkable reduction in the severity and activity of chronic gastritis, marked resolution of intestinal metaplasia in the antrum. On the other hand, continuous H. pylori infection leads to progressive aggravation of atrophy and intestinal metaplasia.

Entities:  

Mesh:

Year:  2003        PMID: 12667379

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  34 in total

1.  Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.

Authors:  Li-Hui Wang; Hong Cheng; Fu-Lian Hu; Jiang Li
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Effects of bile reflux and intragastric microflora changes on lesions of remnant gastric mucosa after gastric operation.

Authors:  Chao Zhang; Zhan-Kui Liu; Pei-Wu Yu
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

3.  Assessing the risks and benefits of treating Helicobacter pylori infection.

Authors:  Ivan F N Hung; Benjamin C Y Wong
Journal:  Therap Adv Gastroenterol       Date:  2009-05       Impact factor: 4.409

Review 4.  Inflammation, atrophy, and gastric cancer.

Authors:  James G Fox; Timothy C Wang
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

5.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

6.  Long-term monitoring of gastric atrophy and intestinal metaplasia after Helicobacter pylori eradication.

Authors:  Kazunari Murakami; Masaaki Kodama; Yoshihumi Nakagawa; Kazuhiro Mizukami; Tadayoshi Okimoto; Toshio Fujioka
Journal:  Clin J Gastroenterol       Date:  2012-06-17

Review 7.  Gastric carcinogenesis.

Authors:  Jan Bornschein; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2011-05-25       Impact factor: 3.445

8.  Anti-Helicobacter pylori activities of Chenopodium ambrosioides L. in vitro and in vivo.

Authors:  Hui Ye; Yu Liu; Ning Li; Jing Yu; Hong Cheng; Jiang Li; Xue-Zhi Zhang
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

9.  Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication.

Authors:  Masaaki Kodama; Kazunari Murakami; Tadayoshi Okimoto; Ryugo Sato; Masahiro Uchida; Takashi Abe; Seiji Shiota; Yoshifumi Nakagawa; Kazuhiro Mizukami; Toshio Fujioka
Journal:  J Gastroenterol       Date:  2011-12-06       Impact factor: 7.527

Review 10.  Optimal therapy for Helicobacter pylori infections.

Authors:  Emiko Rimbara; Lori A Fischbach; David Y Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.